Tag: GlobeNewswire

LITTLE ROCK, Arkansas, Oct. 05, 2026 (GLOBE NEWSWIRE) — Dillard’s, Inc. (“Dillard’s”) (TXSE: DDS) is pleased to announce the launch of Hadley Greene x Gianni Bini, an exclusive, limited-edition fashion collaboration. The collection is available starting today in all Dillard’s stores nationwide and online at dillards.com beginning at 10:00 a.m. CT.

The Hadley Greene x Gianni Bini Collection is available exclusively at Dillard’s.

Born in Texas and raised in Baton Rouge, Louisiana, Hadley Greene is a Los Angeles–based jewelry designer and tastemaker known for her distinct maximalist aesthetic, thoughtful wardrobe curation, and personal style commentary.

“I have fond memories of shopping Dillard’s growing up,” says Greene. “I designed Hadley Greene x Gianni Bini as an ode to my Louisiana heritage and the ease of Los Angeles – the two places that have shaped my sense of creativity and inspiration. We poured an incredible amount of thought and intentionality into every single piece, and everything in the collection has a special, thoughtful backstory.”

A jewelry designer, tastemaker, and storyteller, Hadley is known for a style that strikes the perfect balance between maximalist and timeless, with a one-of-a-kind eye for pieces that feel collected, personal, and enduring. Hadley Greene treats clothing as armor, the first thing you say before you’ve said a word. This collection is that instinct made wearable: expressive, storied, and unmistakably hers.

“We love Hadley’s Baton Rouge roots and her early connection to Dillard’s,” adds Alexandra Dillard Lucie, Vice President of Merchandising. “She brings it all home for our Gianni Bini customer with gorgeous, unique pieces that are sure to inspire head-turning style for every occasion.”

The Hadley Greene x Gianni Bini capsule collection features statement jackets paired with bold separates, dresses, and footwear.

Official Social Channels:

• Hadley Greene Instagram: @hadleyhgreene
• Hadley Greene Substack @hadleyhgreene
• Gianni Bini Instagram: @giannibiniofficial
• Dillard’s Instagram: @dillards

About Hadley Greene
Born in Texas and raised in Baton Rouge, Louisiana, Hadley Greene is a Los Angeles–based jewelry designer and tastemaker. A USC graduate with a degree in Art and Design, she seamlessly blends her passion for effortless expression with a bold, maximalist aesthetic that celebrates individuality. Drawing inspiration from patterns, textures, and unexpected combinations, Hadley crafts jewelry, fashion, and interior designs that are as ornamental as they are authentic. A trailblazer in the fashion and jewelry world, Hadley believes that great design should spark conversation, challenge norms, and inspire creativity. Her work tells an ongoing story of self-expression, where every piece invites a deeper connection with its wearer.

About Gianni Bini
Gianni Bini, Dillard’s largest ladies’ contemporary brand, was launched in 2001 in footwear and later extended to apparel. The mission of Gianni Bini is to remain at the forefront of fashion, offering designs that exude high quality and satisfy the contemporary customer’s constant craving for innovation and trend-forward style. Each season, Gianni Bini delivers fresh yet timeless pieces that speak to every facet of the modern woman’s life.

CONTACT for Dillard’s:
Julie J. Guymon
501-376-5965
julie.guymon@dillards.com

CONTACT for Hadley Greene:
Federica Parruccini
203-253-4196
federica@federicaparruccini.com

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/2f168e61-0bdd-4789-a516-40424c7d7ff0
https://www.globenewswire.com/NewsRoom/AttachmentNg/8d58d1c3-6178-401d-8b8b-713353abbf46
https://www.globenewswire.com/NewsRoom/AttachmentNg/6ac45f61-d308-458e-84ff-489f66ccdc19
https://www.globenewswire.com/NewsRoom/AttachmentNg/964922e7-7255-4bc4-805f-0b3f21fd2e32
https://www.globenewswire.com/NewsRoom/AttachmentNg/baf630f3-28ea-4a8c-ade2-39da6cc2fcbe
https://www.globenewswire.com/NewsRoom/AttachmentNg/e1fe57bc-abc9-456f-8d22-27152702e540
https://www.globenewswire.com/NewsRoom/AttachmentNg/5b49c60c-8722-482b-9704-6a1b0e43133a
https://www.globenewswire.com/NewsRoom/AttachmentNg/b9fb349d-9775-4920-94c0-a32eaaff7578
https://www.globenewswire.com/NewsRoom/AttachmentNg/cbc26d93-9155-41c9-90a1-a570e96a6853

• The BB-301 pivotal trial remains on track to begin in mid-2027
• Discussions regarding an open-label, single-arm, pivotal study for BB-301 are ongoing, and based on these discussions, the FDA requested additional available data, including data from the Benitec-sponsored OPMD Natural History Study
• Final pivotal study design expected to be confirmed in 1Q 2027
• Benitec will present interim clinical results from the ongoing BB-301 Phase 1b/2a study as a late-breaking poster presentation, which will encompass 12-month follow-up data for all six Cohort 1 patients and interim follow-up data for all three Cohort 2 patients, at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress in Hamburg, Germany, October 27-30, 2026

HAYWARD, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage biotechnology company developing disease-modifying genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (ddRNAi) platform, today announced the receipt of formal feedback from the U.S. Food and Drug Administration (FDA) following the Type C meeting in 3Q 2026.

Discussions regarding an open-label, single-arm, pivotal study for BB-301 are ongoing, and based on these discussions, the FDA requested additional available data, including data from the Benitec-sponsored OPMD Natural History Study. The FDA has agreed to review the relevant information on a timeline that would allow Benitec to confirm the final pivotal study design in 1Q 2027.

Timelines for the BB-301 pivotal study remain on track. Patient enrollment is planned to begin in mid-2027.

“We greatly appreciate the collaboration from the FDA and are encouraged by the constructive nature of our discussions” said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec. “The OPMD natural history study was designed from the outset to provide a rigorous foundation for the clinical development of BB-301, and the additional available data requested by the Agency represent an important final component of this ongoing development work. We look forward to providing these data to the FDA in the coming weeks and confirming the pivotal study design for BB-301 in the first quarter of 2027. With the comprehensive body of clinical and natural history data generated to date, we remain on track to initiate the pivotal study in mid-2027 and are focused on advancing BB-301 toward becoming the first approved disease-modifying therapy for patients living with OPMD-related dysphagia.”

Benitec will present interim clinical results from the ongoing BB-301 Phase 1b/2a study as a late-breaking poster presentation, which will encompass 12-month follow-up data for all six Cohort 1 patients and interim follow-up data for all three Cohort 2 patients, at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress in Hamburg, Germany, October 27-30, 2026.

About OPMD

There are currently no approved therapies for OPMD, a rare autosomal-dominant degenerative muscle disorder, that impacts nearly 15,000 patients in North America, Europe and Israel. OPMD is caused by a mutation in the poly(A)-binding protein nuclear 1 (PABPN1) gene; PABPN1 is a ubiquitous protein that controls the length of mRNA poly(A) tails, mRNA export from the nucleus and alternative poly(A) site usage. OPMD is a debilitating progressive disease that weakens the pharyngeal muscles, causing severe swallowing difficulties (dysphagia).¹ Progressive dysphagia impacts 97% of OPMD patients and is a severe, life-threatening complication of OPMD which can lead to chronic choking, malnutrition, aspiration pneumonia and death.

About BB-301

BB-301 is a novel, modified AAV9 capsid expressing a unique, single bifunctional construct promoting co-expression of both codon-optimized Poly-A Binding Protein Nuclear-1 (PABPN1) and two small inhibitory RNAs (siRNAs) against mutant PABPN1 (the causative gene for OPMD). The two siRNAs are modeled into microRNA backbones to silence expression of faulty mutant PABPN1, while allowing expression of the codon-optimized PABPN1 to replace the mutant with a functional version of the protein. BB-301 is administered locally, in a one-time procedure, to the muscles in the throat that drive the swallowing process, an approach designed to maximize local benefit and minimize systemic exposure. We believe the silence and replace mechanism of BB-301 is uniquely positioned for the treatment of OPMD by halting mutant PABPN1 expression while simultaneously providing a functional replacement protein. BB-301 has received Orphan Drug Designation from the EMA and Orphan Drug and Fast Track Designations from the FDA and is currently being evaluated in a Phase 1b/2a, first-in-human, open-label dose escalation study to evaluate the safety and clinical activity of intramuscular doses of BB-301 administered to subjects with OPMD (NCT06185673).

About Benitec Biopharma Inc.

Benitec Biopharma Inc. (NASDAQ: BNTC) is a clinical-stage biotechnology company developing disease-modifying genetic medicines designed to improve the lives of people with life-threatening, genetically defined diseases. The company’s proprietary “Silence and Replace” DNA-directed RNA interference (ddRNAi) platform combines RNA interference, or RNAi, with gene therapy to create medicines designed to facilitate sustained silencing of disease-causing genes and simultaneous delivery of replacement genes that restore normal cellular function following a single administration. The company’s lead investigational candidate, BB-301, is the first and only disease-modifying genetic medicine in clinical development for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagia.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release include forward-looking statements, including statements regarding Benitec’s plans to develop and commercialize its product candidates, the timing of the completion of preclinical and clinical trials, the timing of the availability of data from our clinical trials, the timing and sufficiency of patient enrollment and dosing in clinical trials, the timing of expected regulatory filings and other regulatory steps, and the clinical utility and potential attributes and benefits of ddRNAi and Benitec’s product candidates, and other forward-looking statements.

These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: the success of our plans to develop and potentially commercialize our product candidates; the timing of the completion of preclinical studies and clinical trials; the timing and sufficiency of patient enrollment and dosing in any future clinical trials; the timing of the availability of data from our clinical trials; the timing and outcome of regulatory filings and approvals; the development of novel AAV vectors; our potential future out-licenses and collaborations; the plans of licensees of our technology; the clinical utility and potential attributes and benefits of ddRNAi and our product candidates, including the potential duration of treatment effects and the potential for a “one shot” cure; our intellectual property position and the duration of our patent portfolio; expenses, ongoing losses, future revenue, capital needs and needs for additional financing, and our ability to access additional financing given market conditions and other factors; the length of time over which we expect our cash and cash equivalents to be sufficient to execute on our business plan; unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities; regulatory developments in the United States of America; the Company’s ability to protect and enforce its patents and other intellectual property rights; the Company’s dependence on its relationships with its collaboration partners and other third parties; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace and market competition; reliance on third party manufacturers and suppliers, and the risks associated with manufacturing complexity, supply interruptions, and compliance with current good manufacturing practices, sales, marketing and distribution requirements for our product candidates; greater than expected expenses; including expenses relating to litigation or strategic activities; our incurrence of significant losses and the uncertainty of our ability to achieve or sustain profitability or generate any revenue; the Company’s ability to satisfy its capital needs through increasing revenue and obtaining additional financing; the impact of local, regional, national and international economic conditions and events; including geopolitical instability, and risks associated with conducting business and seeking regulatory approvals in international markets; our ability to attract and retain key management, scientific, and technical personnel; cyber-security threats and vulnerabilities in our and our third parties’ information technology systems; the impact of legislative and regulatory reforms affecting drug pricing and reimbursement, including Medicare drug-price negotiation and government pricing frameworks; potential product liability claims arising from the use of our product candidates in clinical trials or following any future marketing approval; physicians, patients, third-party payers, or others in the medical community may not be receptive to our product candidates, and we may not generate any future revenue from the sale or licensing of our product candidates; and disruptions to U.S. government agency operations, including FDA staffing changes; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission. The Company disclaims any intent or obligation to update these forward-looking statements.

References:

1. https://www.mayoclinic.org/diseases-conditions/dysphagia/symptoms-causes/syc-20372028

Investor Relations Contact:
Candice Masse
astr partners
candice.masse@astrpartners.com

Media Relations Contact:
Audra Friis
Sam Brown Healthcare Communications
(917) 519-9577
audrafriis@sambrown.com

DENVER, Oct. 05, 2026 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, today announced the entry into definitive agreements on October 2, 2026, for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 854,002 shares of SeaStar Medical’s common stock, originally issued in June 2025, July 2025 and August 2025 (collectively, the “Prior Warrants”), having exercise prices ranging from $6.38 to $7.62 per share, at a reduced exercise price of $3.866 per share, for aggregate gross proceeds of approximately $3.3 million, before deducting placement agent fees and other offering expenses. The shares of common stock issuable upon the exercise of the Prior Warrants are registered pursuant to effective registration statements on Form S-1 (Nos. 333-288065 and 333-289447).

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

In consideration for the immediate exercise of the Prior Warrants for cash, SeaStar Medical will issue new unregistered warrants to purchase up to 1,708,004 shares of common stock. The new warrants will have an exercise price of $3.616 per share, and will consist of (i) warrants to purchase up to 854,002 shares of common stock, exercisable immediately and expiring five years after the effective date of the Resale Registration Statement (as defined below), and (ii) warrants to purchase up to 854,002 shares of common stock, exercisable immediately and expiring eighteen months after the effective date of the Resale Registration Statement.

The offering is expected to close on or about October 5, 2026, subject to the satisfaction of customary closing conditions. SeaStar Medical intends to use the net proceeds of this offering for general corporate purposes, which may include additions to working capital and capital expenditures.

The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “Act”), and, along with the shares of common stock issuable upon their exercise, have not been registered under the Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. SeaStar Medical has agreed to file a registration statement within 30 days of October 2, 2026 with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants (the “Resale Registration Statement”).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About SeaStar Medical

SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. SeaStar Medical is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.

For more information visit www.seastarmedical.com or visit us on LinkedIn or X.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements related to the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators; (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to secure additional financing on acceptable terms; (vi) the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services; (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property; (ix) market and other conditions; and (x) other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:  
IR@SEASTARMED.COM

QUELIMMUNE is a registered trademark of SeaStar Medical Holding Corporation.

HIGHLIGHTS 3,933 m of new infill drilling in 36 holes from the Lowhee Zone 1290 m level. Highlight intercepts include: 7.28 g/t Au over 16.15 m (~105 m vertical depth), including 173.66 g/t Au over 0.60 m, 6.80 g/t Au over 0.50 m, 5.39 g/t Au over 0.50 m, and 3.58 g/t Au over 0.50 m 7.13 g/t Au over 11.60 m (~61 m vertical depth), including 62.06 g/t Au over 0.50 m, 31.88 g/t Au over 0.80 m, 18.85 g/t Au over 0.50 m, 7.13 g/t Au over 0.85 m, 6.47 g/t Au over 0.90 m, and 2.23 g/t Au over 0.85 m

TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — Osisko Gold Group Inc. (NYSE: OGG, TSXV: OGG) (“Osisko Gold” or the “Company“) is pleased to announce new results from its ongoing definition infill drilling program on 10-15 metre (“m“) target spacing totaling 3,933 m in 36 holes drilled from the 1290 m level in the Lowhee Zone of the Company’s flagship, permitted, 100%-owned Cariboo Gold Project (the “Project“), currently under construction in central British Columbia, Canada.

Chris Lodder, President, stated, “Ongoing underground infill drilling continues to strengthen our confidence in the Lowhee Zone of the Cariboo Gold deposit. Intercepts outside the modelled reserve stopes also suggest potential for resource conversion and upside mineralization, reinforcing the Cariboo Gold Project’s potential as underground development advances into new zones.”

Corporate Updates

• In connection with the ongoing construction of the Cariboo Gold Project, the Company, through its wholly-owned subsidiary, Barkerville Gold Mines Ltd., has awarded the continuing underground mine development and related works contract to current contractor JDS Energy & Mining Inc. (“JDS“) effective October 5, 2026.
• The Company also announces that it has granted an aggregate of (i) 72,700 stock options of the Company (the “Options“), and (ii) 553,700 restricted share units of the Company (“RSUs“) to certain newly hired senior officers and non-executive employees (collectively, the “Incentive Awards“), pursuant to the Company’s omnibus equity incentive plan (“Omnibus Plan“). The Incentive Awards are designed to align the interests of the recipients with those of shareholders and support the execution of the Company’s long-term growth strategy. The Options are exercisable at a price of C$4.00 per common share of the Company (based on the October 2, 2026, closing price on the TSX Venture Exchange) and will expire on October 5, 2031. The Options will vest in three equal installments over the next three years. The RSUs will cliff vest on October 5, 2029, and are subject to time and performance conditions.

DRILL ASSAY HIGHLIGHTS

This news release contains assays from thirty-six (36) diamond drillholes (“DD“) completed in four fans totaling 3,933 m drilled to the northwest from the L1290-ORE-000 drill station with depths ranging from 81.20 to 150.50 m (see Table 1 and Figures 5-9). All holes were collared in HQ (63.5 millimetre diameter). Estimated true widths of intercepts are provided in Table 1. Select photon assay highlights include:

• 7.28 grams per tonne (“g/t”) gold (“Au”) over 16.15 m at ~105 m vertical depth in BMU-26-121, including:
  • 173.66 g/t Au over 0.60 m, and
  • 6.80 g/t Au over 0.50 m, and
  • 5.39 g/t Au over 0.50 m, and
  • 3.58 g/t Au over 0.50 m
• 7.13 g/t Au over 11.60 m at ~61 m vertical depth in BMU-26-075 (Figure 1), including:
  • 62.06 g/t Au over 0.50 m, and
  • 31.88 g/t Au over 0.80 m, and
  • 18.85 g/t Au over 0.50 m, and
  • 7.13 g/t Au over 0.85 m, and
  • 6.47 g/t Au over 0.90 m, and
  • 2.23 g/t Au over 0.85 m
• 9.40 g/t Au over 8.50 m at ~72 m vertical depth in BMU-26-076, including:
  • 78.39 g/t Au over 0.65 m, and
  • 41.31 g/t Au over 0.55 m, and
  • 3.77 g/t Au over 0.55 m, and
  • 3.06 g/t Au over 0.50 m
• 29.30 g/t Au over 2.10 m at ~62 m vertical depth in BMU-26-096 (Figure 2), including:
  • 111.38 g/t Au over 0.55 m
• 10.26 g/t Au over 5.75 m at ~56 m vertical depth in BMU-26-076, including:
  • 60.62 g/t Au over 0.80 m, and
  • 7.84 g/t Au over 0.50 m, and
  • 5.28 g/t Au over 0.50 m, and
  • 4.82 g/t Au over 0.50 m
• 4.04 g/t Au over 14.35 m at ~78 m vertical depth in BMU-26-098, including:
  • 29.57 g/t Au over 1.00 m, and
  • 20.35 g/t Au over 1.00 m, and
  • 7.06 g/t Au over 0.50 m
• 9.98 g/t Au over 5.70 m at ~91 m vertical depth in BMU-26-118, including:
  • 72.45 g/t Au over 0.60 m, and
  • 8.75 g/t Au over 0.75 m, and
  • 6.38 g/t Au over 0.50 m, and
  • 3.16 g/t Au over 0.50 m
• 11.17 g/t Au over 3.05 m at ~65 m vertical depth in BMU-26-119, including:
  • 50.82 g/t Au over 0.50 m, and
  • 14.38 g/t Au over 0.50 m
• 2.71 g/t Au over 9.95 m at ~63 m vertical depth in BMU-26-097, including:
  • 19.51 g/t Au over 0.95 m, and
  • 6.95 g/t Au over 0.50 m, and
  • 4.87 g/t Au over 0.50 m
• 4.10 g/t Au over 6.50 m at ~40 m vertical depth in BMU-26-047, including:
  • 17.25 g/t Au over 0.50 m, and
  • 14.98 g/t Au over 0.50 m, and
  • 9.18 g/t Au over 0.50 m, and
  • 6.33 g/t Au over 0.50 m, and
  • 2.51 g/t Au over 0.50 m

Complete assay highlights, including true width estimates, are presented in Table 1. Vertical depths are measured from modelled topographic surface to the interval mid-point. Drill hole locations and orientations are listed in Table 2. Intervals not recovered were assigned zero grade. Top cuts have not been applied to high grade assays.

Cut-off assay composites from ongoing infill drilling at the 1290 Level, presented in plan in Figure 5 and in cross section in Figures 6-9, show a degree of spatial correlation with modelled reserve stopes; intercepts outside these areas suggest potential for resource conversion and upside mineralization.

FIGURE 1: 7.13 g/t Au over 11.60 m at ~61 m vertical depth in BMU-26-075

FIGURE 2: Visible gold with pyrite under hand lens in composite interval with 29.30 g/t Au over 2.1 m at ~62 m vertical depth in BMU-26-096

FIGURE 3: Cariboo Gold Project deposit map with Location of Lowhee Zone and Cow Portal underground access.

FIGURE 4: Location and overview of ongoing Lowhee Zone underground definition infill diamond drilling.

FIGURE 5: Lowhee Zone select underground drilling highlights (plan view).

FIGURE 6: L1290-ORE-F09 select underground drill assay highlights (this release) with previously released surface and underground diamond drilling results in cross section by fan. New results from adjacent fans within slice (20 m looking 029°) omitted for visual clarity.

FIGURE 7: L1290-ORE-F10 select underground drill assay highlights (this release) with previously released surface and underground diamond drilling results in cross section by fan. New results from adjacent fans within slice (20 m looking 039°) omitted for visual clarity.

FIGURE 8: L1290-ORE-F11 select underground drill assay highlights (this release) with previously released surface and underground diamond drilling results in cross section by fan. New results from adjacent fans within slice (20 m looking 046°) omitted for visual clarity.

FIGURE 9: L1290-ORE-F12 select underground drill assay highlights (this release) with previously released surface and underground diamond drilling results in cross section by fan. New results from adjacent fans within slice (20 m looking 050°) omitted for visual clarity.

Table 1: Length weighted assay composites and individual samples>=1.8 g/t for Lowhee Zone underground DD.
Drillhole ID		From (m)	To (m)	Length (m)	Au g/t	Est. True Width (m)	Approx. Vertical Depth (m)
BMU-26-047		50.10	51.10	1.00	2.32	0.82	76
	Including	50.10	50.60	0.50	4.38
		83.00	83.50	0.50	2.34	0.41	49
		89.65	96.15	6.50	4.10	4.09	40
	Including	90.15	90.65	0.50	17.25
	and	92.15	92.65	0.50	2.51
	and	92.65	93.15	0.50	14.98
	and	94.15	94.65	0.50	6.33
	and	94.65	95.15	0.50	9.18
		99.30	100.30	1.00	2.67	0.64	34
	Including	99.30	99.80	0.50	4.05
BMU-26-050		85.30	91.80	6.50	1.92	5.37	45
	Including	87.30	87.80	0.50	1.99
	and	87.80	88.40	0.60	4.43
	and	88.90	89.50	0.60	3.74
	and	89.50	90.20	0.70	8.06
		101.65	103.65	2.00	2.96	1.64	33
	Including	102.15	102.65	0.50	9.84
BMU-26-053		48.00	48.50	0.50	2.24	0.38	82
		123.00	123.50	0.50	17.80	0.43	21
BMU-26-056		11.10	11.60	0.50	1.87	0.48	113
		46.90	48.40	1.50	3.52	1.45	85
	Including	47.40	47.90	0.50	10.26
		78.80	79.30	0.50	1.92	0.33	61
BMU-26-059		11.00	11.50	0.50	2.53	0.45	114
		35.90	36.40	0.50	2.11	0.49	97
		43.50	44.00	0.50	3.42	0.46	91
		87.00	89.50	2.50	2.21	2.48	61
	Including	87.00	87.50	0.50	2.66
	and	88.50	89.00	0.50	7.90
		93.60	94.10	0.50	2.07	0.50	58
BMU-26-062		11.00	11.50	0.50	3.41	0.49	115
		42.50	44.00	1.50	2.06	1.31	96
	Including	43.00	43.50	0.50	5.68
		60.20	61.70	1.50	2.97	1.48	86
	Including	61.20	61.70	0.50	7.79
		78.50	80.50	2.00	1.98	1.34	76
	Including	80.00	80.50	0.50	7.02
		84.80	86.30	1.50	6.27	1.15	73
	Including	85.30	85.80	0.50	18.52
BMU-26-065		12.00	12.50	0.50	3.57	0.43	116
		42.00	42.50	0.50	6.51	0.50	100
		60.50	61.00	0.50	3.24	0.41	92
		63.60	64.10	0.50	7.64	0.49	91
		67.60	68.10	0.50	5.01	0.48	89
BMU-26-067		13.40	14.90	1.50	1.98	1.30	117
	Including	13.40	13.90	0.50	2.99
	and	13.90	14.40	0.50	2.73
		41.40	43.00	1.60	5.23	1.59	109
	Including	41.40	41.90	0.50	16.43
		59.40	59.90	0.50	2.99	0.50	104
		63.40	63.90	0.50	1.95	0.50	103
		73.80	74.30	0.50	6.95	0.49	101
BMU-26-069		0.00	1.00	1.00	2.12	0.97	122
		14.50	15.00	0.50	13.87	0.46	119
		39.10	39.60	0.50	21.45	0.49	116
		45.00	49.50	4.50	2.10	4.04	115
	Including	45.00	45.50	0.50	13.23
	and	48.50	49.00	0.50	4.15
		82.20	87.00	4.80	2.66	4.51	115
	Including	82.20	82.70	0.50	15.58
	and	84.45	84.95	0.50	2.13
	and	86.00	87.00	1.00	3.81
BMU-26-070		35.10	35.60	0.50	2.31	0.43	124
		48.40	48.90	0.50	6.76	0.37	126
		59.00	59.50	0.50	4.03	0.32	127
		73.40	74.00	0.60	6.88	0.49	130
		88.40	90.25	1.85	1.94	1.06	134
	Including	89.20	89.75	0.55	3.87
BMU-26-072		39.10	40.60	1.50	5.43	1.45	87
	Including	39.60	40.10	0.50	15.77
		69.50	70.50	1.00	3.09	0.64	63
	Including	69.50	70.00	0.50	6.05
BMU-26-073		37.90	39.50	1.60	9.89	1.31	90
	Including	37.90	38.40	0.50	24.86
	and	38.40	39.00	0.60	5.54
		50.65	51.30	0.65	3.16	0.56	80
BMU-26-074		36.05	37.05	1.00	2.24	0.95	93
	Including	36.55	37.05	0.50	3.92
		48.20	49.20	1.00	4.23	0.95	84
	Including	48.20	48.70	0.50	8.30
		84.20	85.20	1.00	10.13	0.87	57
	Including	84.20	84.70	0.50	19.94
		99.05	102.40	3.35	2.98	3.15	45
	Including	101.60	102.40	0.80	11.02
BMU-26-075		10.80	11.30	0.50	2.85	0.47	114
		74.80	76.90	2.10	1.97	1.67	68
	Including	75.40	75.90	0.50	2.10
	and	75.90	76.90	1.00	2.99
		79.40	91.00	11.60	7.13	11.30	61
	Including	79.90	80.40	0.50	18.85
	and	81.70	82.50	0.80	31.88
	and	83.00	83.50	0.50	62.06
	and	86.55	87.40	0.85	2.23
	and	87.40	88.25	0.85	7.13
	and	90.10	91.00	0.90	6.47
		97.00	98.00	1.00	2.18	0.91	53
	Including	97.00	97.50	0.50	4.21
BMU-26-076		72.50	81.00	8.50	9.40	7.94	72
	Including	73.75	74.25	0.50	3.06
	and	75.10	75.65	0.55	41.31
	and	75.65	76.20	0.55	3.77
	and	76.20	76.85	0.65	78.39
		91.00	94.00	3.00	2.14	2.72	61
	Including	93.00	93.50	0.50	11.15
		97.60	103.35	5.75	10.26	5.21	56
	Including	99.50	100.00	0.50	4.82
	and	100.50	101.30	0.80	60.62
	and	101.30	101.80	0.50	5.28
	and	102.85	103.35	0.50	7.84
		110.40	111.90	1.50	2.75	1.43	48
	Including	110.40	110.90	0.50	2.42
	and	110.90	111.40	0.50	5.60
		113.30	114.30	1.00	8.23	1.00	46
	Including	113.30	113.80	0.50	15.88
BMU-26-077		7.50	8.00	0.50	2.59	0.49	118
		78.10	79.15	1.05	3.56	1.05	79
	Including	78.10	78.60	0.50	3.84
	and	78.60	79.15	0.55	3.32
		81.75	82.25	0.50	1.92	0.49	77
BMU-26-078		42.00	42.50	0.50	2.25	0.50	102
		68.50	69.50	1.00	1.97	0.97	91
	Including	68.50	69.00	0.50	3.22
		86.00	89.00	3.00	3.49	2.12	84
	Including	86.00	86.50	0.50	17.99
BMU-26-079		12.70	13.70	1.00	13.56	0.71	118
	Including	13.20	13.70	0.50	26.97
		43.90	45.40	1.50	3.90	1.43	109
	Including	44.90	45.40	0.50	11.51
		63.00	63.50	0.50	6.36	0.50	105
		69.60	71.10	1.50	2.53	1.48	103
	Including	69.60	70.10	0.50	7.08
		73.10	73.60	0.50	3.49	0.47	103
		79.00	81.10	2.10	5.88	2.07	101
	Including	80.60	81.10	0.50	24.35
BMU-26-080		14.80	15.30	0.50	18.58	0.45	120
		49.40	49.90	0.50	3.38	0.43	117
		71.50	72.00	0.50	2.60	0.48	117
		82.40	85.20	2.80	1.80	2.42	118
	Including	82.90	83.80	0.90	4.40
BMU-26-081		15.80	17.10	1.30	6.20	1.06	124
	Including	16.60	17.10	0.50	15.63
		44.35	44.85	0.50	3.00	0.43	127
		46.50	47.00	0.50	3.01	0.43	127
		53.65	54.70	1.05	3.70	0.80	128
	Including	54.20	54.70	0.50	7.53
		58.60	59.10	0.50	1.81	0.38	129
		77.50	79.00	1.50	5.23	1.15	133
	Including	77.50	78.00	0.50	15.19
		80.35	80.85	0.50	3.76	0.43	134
BMU-26-093		6.00	7.00	1.00	1.87	0.87	116
		68.00	71.05	3.05	3.07	2.64	67
	Including	68.90	69.40	0.50	2.01
	and	69.40	69.95	0.55	8.82
	and	69.95	70.55	0.60	3.27
BMU-26-094		36.00	39.05	3.05	5.23	2.74	93
	Including	38.05	38.55	0.50	29.40
		41.50	42.55	1.05	2.84	0.91	89
	Including	42.00	42.55	0.55	5.00
		57.00	57.50	0.50	1.94	0.35	78
		61.00	65.70	4.70	3.84	3.23	74
	Including	62.55	63.20	0.65	18.46
	and	63.70	64.20	0.50	7.34
	and	64.70	65.20	0.50	2.51
BMU-26-095		35.90	39.40	3.50	4.54	3.29	95
	Including	37.40	37.90	0.50	29.01
		65.90	66.40	0.50	3.04	0.47	75
BMU-26-096		68.30	70.80	2.50	3.39	2.17	77
	Including	68.30	68.80	0.50	2.50
	and	68.80	69.30	0.50	13.72
		91.40	93.50	2.10	29.30	1.79	62
	Including	91.90	92.45	0.55	111.38
		119.40	119.90	0.50	1.97	0.23	42
BMU-26-097		35.75	36.25	0.50	2.00	0.49	101
		67.25	77.10	9.85	1.95	9.44	81
	Including	67.75	68.55	0.80	3.63
	and	70.80	71.70	0.90	7.62
	and	72.80	73.50	0.70	2.44
	and	74.00	74.50	0.50	3.28
	and	74.50	75.00	0.50	8.49
		88.30	89.80	1.50	2.42	1.30	71
	Including	88.80	89.30	0.50	6.94
		97.00	106.95	9.95	2.71	8.76	63
	Including	97.00	97.50	0.50	6.95
	and	98.85	99.80	0.95	19.51
	and	106.45	106.95	0.50	4.87
		111.50	114.00	2.50	1.81	2.41	57
	Including	113.00	113.50	0.50	8.56
		130.80	137.00	6.20	2.32	5.99	47
	Including	133.25	133.75	0.50	14.79
	and	134.80	135.50	0.70	2.10
	and	135.50	136.25	0.75	3.77
BMU-26-098		65.75	67.50	1.75	2.44	1.74	89
	Including	65.75	66.25	0.50	7.65
		81.00	95.35	14.35	4.04	11.51	78
	Including	89.50	90.50	1.00	29.57
	and	92.00	92.50	0.50	7.06
	and	92.50	93.50	1.00	20.35
		107.40	119.50	12.10	2.07	10.48	65
	Including	107.40	108.00	0.60	3.44
	and	110.50	111.15	0.65	5.14
	and	111.65	112.15	0.50	8.08
	and	112.90	113.40	0.50	4.50
	and	113.40	113.90	0.50	13.82
	and	114.40	115.40	1.00	2.26
	and	115.40	116.00	0.60	1.98
BMU-26-099		83.50	85.50	2.00	2.12	1.47	89
	Including	85.00	85.50	0.50	7.35
		92.20	92.85	0.65	1.92	0.59	86
		94.35	97.00	2.65	1.83	2.25	85
	Including	94.85	95.85	1.00	2.33
BMU-26-100		11.20	12.20	1.00	10.38	0.97	120
	Including	11.70	12.20	0.50	19.78
		44.90	47.00	2.10	2.04	2.07	112
	Including	44.90	45.50	0.60	5.87
		66.00	69.00	3.00	2.85	2.90	109
	Including	68.50	69.00	0.50	16.13
		76.40	77.25	0.85	2.48	0.84	108
		90.00	91.50	1.50	2.83	1.06	106
	Including	91.00	91.50	0.50	8.26
		104.65	106.50	1.85	1.87	1.82	104
	Including	104.65	105.15	0.50	5.19
BMU-26-101		14.05	16.70	2.65	2.07	2.29	122
	Including	14.70	15.20	0.50	7.87
	and	15.20	15.70	0.50	2.47
		48.10	51.90	3.80	4.85	3.20	120
	Including	51.40	51.90	0.50	34.71
		66.00	68.50	2.50	2.19	2.25	121
	Including	68.00	68.50	0.50	10.61
		73.50	74.50	1.00	2.99	0.87	121
	Including	73.50	74.00	0.50	5.89
		90.10	91.10	1.00	4.60	0.71	122
	Including	90.10	90.60	0.50	8.92
		106.00	111.00	5.00	2.24	4.05	124
	Including	106.00	106.55	0.55	1.88
	and	108.00	108.50	0.50	7.79
	and	109.00	109.50	0.50	11.12
BMU-26-102		2.70	3.30	0.60	2.95	0.41	124
		8.30	8.80	0.50	1.85	0.35	124
		9.40	10.60	1.20	1.90	0.69	124
	Including	9.40	10.10	0.70	2.15
		17.00	17.50	0.50	10.93	0.41	124
		37.10	38.10	1.00	8.37	0.77	127
	Including	37.10	37.60	0.50	16.46
		58.30	58.80	0.50	3.21	0.35	131
BMU-26-116		16.20	16.80	0.60	2.36	0.42	124
		49.50	50.05	0.55	3.03	0.39	127
		53.15	53.65	0.50	2.41	0.45	128
		68.15	69.15	1.00	8.65	0.94	130
	Including	68.65	69.15	0.50	16.99
		72.50	73.00	0.50	2.32	0.43	131
		87.60	88.10	0.50	2.01	0.43	133
		89.70	90.30	0.60	4.63	0.52	134
		110.80	113.50	2.70	3.86	2.54	139
	Including	111.30	111.80	0.50	18.27
	and	111.80	112.40	0.60	1.81
		115.55	116.05	0.50	3.61	0.47	140
		119.00	119.50	0.50	2.01	0.47	140
BMU-26-117		11.50	13.30	1.80	2.35	1.63	121
	Including	12.30	12.80	0.50	7.95
		47.40	47.90	0.50	2.69	0.43	118
		93.40	93.90	0.50	2.40	0.43	118
		104.90	106.40	1.50	4.35	1.15	119
	Including	105.40	105.90	0.50	12.04
		116.50	117.00	0.50	2.43	0.35	120
BMU-26-118		10.90	11.90	1.00	8.87	0.94	119
	Including	10.90	11.40	0.50	17.52
		77.50	78.50	1.00	2.99	1.00	99
	Including	77.50	78.00	0.50	5.89
		98.40	99.40	1.00	2.40	0.94	94
	Including	98.40	98.90	0.50	2.46
	and	98.90	99.40	0.50	2.33
		110.90	116.60	5.70	9.98	5.36	91
	Including	111.45	111.95	0.50	6.38
	and	111.95	112.55	0.60	72.45
	and	112.55	113.30	0.75	8.75
	and	113.30	113.80	0.50	3.16
BMU-26-119		34.50	35.00	0.50	4.24	0.47	104
		44.50	46.00	1.50	5.55	1.48	99
	Including	44.50	45.00	0.50	15.26
		64.00	66.00	2.00	2.40	1.81	90
	Including	64.00	64.70	0.70	6.19
		88.90	89.40	0.50	27.24	0.47	77
		100.90	105.90	5.00	2.07	4.83	69
	Including	100.90	101.40	0.50	2.18
	and	101.40	102.00	0.60	1.90
	and	102.00	102.50	0.50	8.41
	and	102.50	103.00	0.50	1.92
	and	104.00	104.50	0.50	3.21
	and	105.40	105.90	0.50	1.90
		111.20	114.25	3.05	11.17	2.34	65
	Including	111.75	112.25	0.50	50.82
	and	113.25	113.75	0.50	14.38
BMU-26-120		24.00	25.00	1.00	1.81	0.91	106
	Including	24.50	25.00	0.50	3.49
		33.30	34.70	1.40	6.97	1.21	99
	Including	33.30	34.20	0.90	10.78
		52.50	54.50	2.00	3.30	1.73	87
	Including	53.00	53.50	0.50	12.86
BMU-26-121		14.25	30.40	16.15	7.28	13.99	105
	Including	17.90	18.40	0.50	3.58
	and	18.40	19.00	0.60	173.66
	and	26.60	27.10	0.50	6.80
	and	29.90	30.40	0.50	5.39
		39.00	40.90	1.90	1.95	1.72	91
	Including	39.90	40.40	0.50	6.63
		47.90	51.00	3.10	1.98	1.99	85
	Including	48.90	49.40	0.50	5.50
	and	49.40	49.90	0.50	1.84
		52.00	53.00	1.00	1.96	0.94	82
	Including	52.50	53.00	0.50	2.79
		56.90	58.00	1.10	2.56	0.84	79
	Including	57.40	58.00	0.60	4.56

Table 2: Underground DD collar locations, drillhole orientations, and max depths. Negative dips point down.
Drillhole ID	Mine Location	Easting (UTM Zn 10N)	Northing (UTM Zn 10N)	Elevation (m)	Dip	Azimuth	Depth (m)
BMU-26-047	L1290-ORE-000	596489	5882890	1292	33	302	123.20
BMU-26-050	L1290-ORE-000	596489	5882890	1292	28	302	126.30
BMU-26-053	L1290-ORE-000	596489	5882890	1291	22	302	132.40
BMU-26-056	L1290-ORE-000	596489	5882890	1291	16	302	112.90
BMU-26-059	L1290-ORE-000	596489	5882890	1291	10	302	103.90
BMU-26-062	L1290-ORE-000	596489	5882890	1290	3	302	96.50
BMU-26-065	L1290-ORE-000	596489	5882890	1290	-4	302	93.30
BMU-26-067	L1290-ORE-000	596489	5882890	1290	-16	302	87.40
BMU-26-069	L1290-ORE-000	596489	5882890	1290	-27	302	87.50
BMU-26-070	L1290-ORE-000	596489	5882890	1289	-38	302	96.20
BMU-26-072	L1290-ORE-000	596489	5882890	1292	33	309	96.20
BMU-26-073	L1290-ORE-000	596489	5882890	1292	28	309	111.30
BMU-26-074	L1290-ORE-000	596489	5882890	1291	22	309	120.40
BMU-26-075	L1290-ORE-000	596489	5882890	1291	16	309	118.90
BMU-26-076	L1290-ORE-000	596489	5882890	1291	10	309	114.30
BMU-26-077	L1290-ORE-000	596489	5882890	1290	3	309	113.10
BMU-26-078	L1290-ORE-000	596489	5882890	1290	-4	309	102.30
BMU-26-079	L1290-ORE-000	596489	5882890	1290	-17	309	93.40
BMU-26-080	L1290-ORE-000	596489	5882890	1289	-27	309	97.30
BMU-26-081	L1290-ORE-000	596489	5882890	1289	-38	309	105.20
BMU-26-093	L1290-ORE-000	596490	5882890	1292	33	316	81.30
BMU-26-094	L1290-ORE-000	596490	5882890	1292	28	316	81.20
BMU-26-095	L1290-ORE-000	596489	5882890	1291	22	316	87.40
BMU-26-096	L1290-ORE-000	596490	5882890	1291	17	316	150.50
BMU-26-097	L1290-ORE-000	596490	5882890	1291	10	317	137.00
BMU-26-098	L1290-ORE-000	596490	5882890	1290	3	316	122.00
BMU-26-099	L1290-ORE-000	596489	5882890	1290	-4	316	116.00
BMU-26-100	L1290-ORE-000	596489	5882891	1290	-16	316	113.00
BMU-26-101	L1290-ORE-000	596489	5882891	1289	-27	316	114.50
BMU-26-102	L1290-ORE-000	596490	5882890	1289	-38	316	111.30
BMU-26-116	L1290-ORE-000	596490	5882891	1289	-33	320	120.50
BMU-26-117	L1290-ORE-000	596490	5882891	1289	-21	320	119.00
BMU-26-118	L1290-ORE-000	596490	5882891	1290	-7	320	126.50
BMU-26-119	L1290-ORE-000	596490	5882891	1291	7	320	134.00
BMU-26-120	L1290-ORE-000	596490	5882890	1291	21	320	89.00
BMU-26-121	L1290-ORE-000	596490	5882890	1292	33	320	97.90

ABOUT LOWHEE ZONE

Geological mapping and geochemical sampling were carried out on Barkerville Mountain from 2017-2018, with the Lowhee Zone identified as a high-priority drill target. From 2019 to 2022, a total of 167 surface drill holes were completed, totaling 54,494.5 m.

The Lowhee Zone is accessed through the Cow portal on the northwestern flank of Barkerville Mountain (Figure 3 and Figure 4). Cow portal construction was completed in Q4 2024 and development of the underground ramp into the Lowhee Zone commenced in Q1 2025. The probable mineral reserves estimate for the Lowhee Zone (with an effective date of April 10, 2025) includes 104,491 ounces of contained Au (923,162 tonnes grading 3.52 g/t Au) and represents approximately 5% of the total contained gold in the estimated probable mineral reserves for the Cariboo Gold Project.

ABOUT CARIBOO GOLD PROJECT

The Cariboo Gold Project is a permitted, 100%-owned feasibility-stage project currently under construction located in the historic Wells-Barkerville mining camp of central British Columbia, Canada. Spanning approximately 186,740 hectares, the Company’s land package includes 443 mineral titles and covers an area that extends approximately 77 kilometres from northwest to southeast. In late 2024, the Project was granted the Mines Act and Environmental Management Act (British Columbia) permits, marking the successful completion of the permitting process for key approvals. On September 14, 2026, the Company announced a formal positive decision to proceed with the construction of the Project, with an expected first gold pour in Q1 2029 and commercial production in H2 2029.

Technical Reports

Scientific and technical information relating to the Cariboo Gold Project and the 2025 feasibility study on the Cariboo Gold Project is supported by the technical report, titled “NI 43-101 Technical Report, Feasibility Study for the Cariboo Gold Project, District of Wells, British Columbia, Canada” and dated June 11, 2025 (with an effective date of April 25, 2025) (the “Cariboo Technical Report“).

For readers to fully understand the information in the Cariboo Technical Report, reference should be made to the full text of the Cariboo Technical Report in its entirety, including all assumptions, parameters, qualifications, limitations and methods therein. The Cariboo Technical Report is intended to be read as a whole, and sections should not be read or relied upon out of context. The Cariboo Technical Report was prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101“) and is available electronically on SEDAR+ (www.sedarplus.ca) and on EDGAR (www.sec.gov) under Osisko Gold’s issuer profile and on the Company’s website at www.osiskogold.ca.

Qualified Persons

The scientific and technical information in this news release has been reviewed, verified and approved by Scott Smith, P. Geo., Vice President, Exploration of Osisko Gold, a “qualified person” within the meaning of NI 43-101. Verification includes core photo and three-dimensional review of logged drillhole data and assays consistent with the Company’s standard procedures.

Quality Assurance (QA) – Quality Control (QC)

All drill core was whole core sampled in on-site logging facilities following daily QAQC checks for logging and sampling errors. Quality control (QC) samples are inserted at regular intervals in the sample stream, including blanks and reference materials with all sample shipments to monitor laboratory performance. Samples are bagged, labelled, sealed with numbered security tags.

Samples are taken by expeditor from the logging facilities direct to MSALABS’s analytical facility in Prince George, B.C., Canada, for preparation and analysis. MSALABS is independent of the Company. The MSALABS facility is accredited to the ISO/IEC 17025 standard for gold assays, and all analytical methods include quality control materials at set frequencies with established data acceptance criteria. The entire sample is dried, crushed, and split into sealed containers. Analysis for gold is by gamma ray analysis using the Chrysos PhotonAssay (PA1408X). Samples are bombarded with gamma rays and the resulting signal is sent to the detectors.

ABOUT OSISKO GOLD GROUP INC.
Osisko Gold Group Inc. is a North American gold development company focused on past-producing mining camps with district-scale potential. The Company’s objective is to become an intermediate gold producer through the development of its flagship, fully permitted, 100%-owned Cariboo Gold Project, currently under construction in central British Columbia, Canada. The Project is situated within the Company’s broader Cariboo regional land package, which hosts numerous prospective exploration targets and provides opportunities for future discoveries. Its Cariboo project pipeline is complemented by the Tintic Project, located in the historic East Tintic mining district in Utah, U.S.A., a brownfield property with significant exploration potential, extensive historical mining data, and access to established infrastructure. Osisko Gold is focused on developing long-life mining assets in mining-friendly jurisdictions while maintaining a disciplined approach to capital allocation, development risk management, and mineral inventory growth. For further information, visit our website at www.osiskogold.ca or contact:
Sean Roosen Chairman and CEO Email: sroosen@osiskogold.ca Tel: +1 (514) 940-0685	Philip Rabenok Vice President, Investor Relations Email: prabenok@osiskogold.ca Tel: +1 (437) 423-3644

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This news release contains “forward-looking information” (within the meaning of applicable Canadian securities laws) and “forward-looking statements” (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended) (collectively, “forward-looking statements”). Such forward-looking statements are identified with words such as “may”, “will”, “would”, “could”, “anticipate”, “believe”, “expect”, “plan”, “intend”, “potential”, “estimate”, “propose”, “project”, “outlook”, “foresee”, “objective”, “strategy”, variants of these words or the negative or comparable terminology, as well as terms usually used in the future and the conditional. Information contained in forward-looking statements is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including the assumptions, qualifications, limitations or statements pertaining to: the utility and significance of the underground infill drilling results and the interpretation thereof; the interpretation and accuracy of intercepts outside modelled reserve stopes to suggest potential for resource conversion and upside mineralization (if at all); the potential for upside at depth and along strike of the known mineral resource footprint (if any); the interpretation and accuracy of spatial geometries, geological structure and local variability modeling and assumptions in regard to potential reserve or resource revisions (if at all); the ability and utility of exploration and infill drilling to inform resource modeling, mine planning, production stope design procedures and parameters, refinement of infill drill requirements, and the appropriate drill spacing for future infill drilling (if at all); the results (if any) of further exploration work and ability of the Company to define and expand mineral resources beyond current mineral resource estimates; mineral resource category conversion; the prospectivity of exploration in targets outside of currently defined mineral reserves and/or mineral resources; the performance of the underground mine development and related works contract with JDS and the advancement of underground development into new zones; the anticipated construction of the Cariboo Gold Project, including the expected timing of first gold pour and commercial production; the vesting, exercise and settlement of the Incentive Awards, including the satisfaction of applicable time and performance conditions; assumptions, qualifications and parameters underlying the Cariboo Technical Report (including, but not limited to, the mineral resources, mineral reserves, production profile, mine design and project economics); the results of the Cariboo Technical Report as an indicator of quality and robustness of the Cariboo Gold Project; the ability of the Company to achieve the estimates outlined in the Cariboo Technical Report in the timing contemplated (if at all); the future development and operations at the Cariboo Gold Project; management’s perceptions of historical trends, current conditions and expected future developments; the utility and significance of historic data, including the significance of the district hosting past producing mines; the ability of exploration work (including drilling and sampling) to accurately predict mineralization; the ability of the Company to complete its exploration and development objectives for its projects in the timing contemplated and within expected costs (if at all); the ability to adapt to changes in gold prices, estimates of costs, estimates of planned exploration and development expenditures; the Company’s strategy and objectives relating to the Cariboo Gold Project as well as its other projects; the assumptions, qualifications and limitations relating to the Cariboo Gold Project being permitted; the exploration potential and prospectivity (if any) of its properties; ‘regulatory framework remaining defined and understood as well as other considerations that are believed to be appropriate in the circumstances, and any other information herein that is not a historical fact may be “forward looking information”. Actual results could differ materially due to a number of factors, including, without limitation: ‘risks relating to third-party approvals, including the issuance of permits by governments; risks relating to the performance of contractors, including JDS; capital market conditions and the Company’s ability to access capital on terms acceptable to the Company for the contemplated exploration, development and construction at the Company’s properties; risks related to the exploration, development, construction and operation of the Cariboo Gold Project, including delays and cost overruns; risks related to geological modeling and resource estimation; health, safety and security incidents; regulatory delays or changes in regulatory framework and applicable laws; labour shortages or disputes; general economic and market conditions and business conditions in the mining industry; fluctuations in commodity prices and currency exchange rates, as well as those risks and factors disclosed in the Company’s most recent annual information form, financial statements and management’s discussion and analysis as well as other public filings on SEDAR+ (www.sedarplus.ca) and on EDGAR (www.sec.gov).

Although the Company believes the expectations conveyed by the forward-looking statements are reasonable based on information available as of the date hereof, no assurances can be given as to future results, levels of activity and achievements. The Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by law. Forward-looking statements are not guarantees of performance and there can be no assurance that these forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/048644ec-c3aa-4b42-ad5d-56c5f881f67e

https://www.globenewswire.com/NewsRoom/AttachmentNg/6db64776-06a9-4634-aabf-839b83d2b32d

https://www.globenewswire.com/NewsRoom/AttachmentNg/f81c7779-869f-4326-b4ed-88f88b8243f1

https://www.globenewswire.com/NewsRoom/AttachmentNg/f175af7f-59c7-4e6b-90e7-aa36b9d81523

https://www.globenewswire.com/NewsRoom/AttachmentNg/b8df43eb-da48-4eb6-a4db-e3ea2bd258b8

https://www.globenewswire.com/NewsRoom/AttachmentNg/4c1dae29-f486-47ca-a3a5-bc6bdef4f347

https://www.globenewswire.com/NewsRoom/AttachmentNg/14788e02-f83e-4666-ad26-3b92f63277f5

https://www.globenewswire.com/NewsRoom/AttachmentNg/b3762a5b-1add-4149-b3ab-fb76fb1dce51

https://www.globenewswire.com/NewsRoom/AttachmentNg/ea7ce0b0-1ea1-4a2b-8947-3643c763f0dc

ROCHESTER, NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) — Syntec Optics Holdings, Inc. (Nasdaq: OPTX) (“Syntec Optics” or the “Company”), a leading provider of deep-tech products to defense, space, and AI data centers, today announced recurring production orders for actuators in NASA’s Artemis III rockets. 

Rockets need absolute precision to stay on a course full of adversity—like a unicyclist on a tightrope in a hurricane. Syntec Optics makes the ultra-precise products inside rocket actuators that keep those heavy engines locked on trajectory.

As NASA Administrator Jared Isaacman fast-tracks and modernizes America’s space infrastructure toward a $20B Moon base for mining, data centers, and future fusion fuel, the global rocket market is surging from $10.5 billion in 2023 to $24.4 billion by 2030.

“We feel privileged to bridge generations,” said Matt Carey, VP of Business Development. “We are working side-by-side with the pioneers of the Apollo and Space Shuttle eras to create the modern hardware that will return humanity to the Moon. Unlike the old Apollo visits, which seemed like short trips to win a space race, this new push aims to stay.”

With the Artemis III mission strategy evolving to include rigorous Earth-orbit practice tests for landers and docking systems ahead of the lunar landing, Syntec is locking in years of recurring orders.

“NASA’s strategic pivot establishes a foundation of predictable, high-value orders, immediately boosting our space tech backlog further by 10% and positioning our lunar products for exponential growth as moon missions accelerate,” noted CFO Dean Rudy.

Precision-engineered products, from satellite communications and safety to Space Force reconnaissance and lunar rockets, make Syntec a vital partner in securing America’s space dominance. 

About Syntec Optics

Headquartered in Rochester, N.Y., Syntec Optics Holdings, Inc. (NASDAQ: OPTX) is one of the nation’s largest bespoke manufacturers of high-precision optics and photonics. With a dedicated team of nearly 180 employees, the company pushes the limits of light-based technologies to connect and protect the world. Syntec supports critical missions ranging from low-Earth-orbit satellites to advanced connected-battlefield defense platforms, AI data centers, and life sciences. As light-enabled technologies continue to account for a significant portion of global economic output—representing nearly $20 trillion of the $111 trillion in total worldwide production as of 2024—Syntec Optics remains positioned at the forefront of the modern optical revolution.

For more information, visit syntecoptics.com.

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this press release, including statements as to the intended use of net proceeds from the public offering, are forward-looking statements. Some of these forward-looking statements can be identified by the use of forward-looking words, including “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “plan,” “targets,” “projects,” “could,” “would,” “continue,” “forecast” or the negatives of these terms or variations of them or similar expressions. All forward-looking statements are subject to risks, uncertainties, and other factors (some of which are beyond the control of Syntec Optics), which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. All forward-looking statements are based upon estimates, forecasts and assumptions that, while considered reasonable by Syntec Optics and its management, as the case may be, are inherently uncertain and many factors may cause the actual results to differ materially from current expectations which include, but are not limited to: 1) risk outlined in any prior SEC filings; 2) ability of Syntec Optics to successfully increase market penetration into its target markets; 3) the addressable markets that Syntec Optics intends to target do not grow as expected; 4) the loss of any key executives; 5) the loss of any relationships with key suppliers including suppliers abroad; 6) the loss of any relationships with key customers; 7) the inability to protect Syntec Optics’ patents and other intellectual property; 8) the failure to successfully execute manufacturing of announced products in a timely manner or at all, or to scale to mass production; 9) costs related to any further business combination; 10) changes in applicable laws or regulations; 11) the possibility that Syntec Optics may be adversely affected by other economic, business and/or competitive factors; 12) Syntec Optics’ estimates of its growth and projected financial results for the future and meeting or satisfying the underlying assumptions with respect thereto; 13) the impact of any pandemic, including any mutations or variants thereof and the Russian/Ukrainian or Israeli conflict, and any resulting effect on business and financial conditions; 14) inability to complete any investments or borrowings in connection with any organic or inorganic growth; 15) the potential for events or circumstances that result in Syntec Optics’ failure to timely achieve the anticipated benefits of Syntec Optics’ customer arrangements; and 16) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in prior SEC filings. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Syntec Optics does not give any assurance that Syntec Optics will achieve its expected results. Syntec Optics does not undertake any duty to update these forward-looking statements except as otherwise required by law.

For further information, please contact:

Investor Relations

InvestorRelations@syntecoptics.com 

SOURCE: Syntec Optics Holdings, Inc. (Nasdaq: OPTX)

In week 40 Kvika banki hf. purchased 10,500,000 of its own shares at the purchase price ISK 130,305,000. See further details below:

Date	Time	No. of shares	Share price	Purchase price
28.09.2026	13:38:29	2,000,000	12.45	24,900,000
28.09.2026	13:43:17	700,000	12.45	8,715,000
29.08.2026	10:23:40	1,000,000	12.45	12,450,000
29.08.2026	15:03:43	1,500,000	12.425	18,637,500
30.09.2026	10:00:17	500,000	12.425	6,212,500
30.09.2026	12:37:33	2,000,000	12.425	24,850,000
01.10.2026	09:40:34	2,000,000	12.35	24,700,000
01.10.2026	09:57:10	800,000	12.3	9,840,000
Total		10,500,000		130,305,000

The trade is in accordance with Kvika‘s buyback programme, announced on 11 September 2026, based on the authorisation of the bank’s Annual General Meeting on 18 March 2026.

Kvika has now purchased a total of 21,695,000 shares under the buyback programme, which corresponds to 0.501% of issued shares in the company. The total purchase price is ISK 268,097,875. Following these transactions Kvika holds 63,431,460 of own shares which corresponds to 1.465% of issued shares.

Buyback under the programme will be limited to an aggregate purchase price of up to ISK 1,540,550,041 and no more than 165,500,003 shares.

The buyback programme will remain in effect until shares have been repurchased for an aggregate consideration of ISK 1,540,550,041 or 165,500,003 shares have been acquired, whichever occurs first, but no later than 30 April 2027.

The execution of the buy-back programme must comply with Act on Public Limited Companies. No. 2/1995. In addition. the buy-back programme must be implemented as provided for in the Regulation of the European Parliament and of the Council no. 596/2014. on market abuse. as well as the Commission Delegated Regulation (EU) 2016/1052 on regulatory technical standards for the conditions applicable to buy-back programmes and stabilisation measures. which supplements that Regulation.

Further information please contact Kvika‘s investor relations, ir@kvika.is.

To Nasdaq Copenhagen A/S

Executive Management Bernstorffsgade 40 DK-1577 København V www.rd.dk Telephone +45 7012 5300 5 October 2026

Company Announcement 05.10.2026

Repayments, Realkredit Danmark A/S

Pursuant to §24 of the Capital Markets Act, Realkredit Danmark A/S hereby publishes repayments as at
1 October 2026.
Please find the data in the attached file.

The information will also be available on www.rd.dk.

Yours sincerely

The Executive Management

Any additional questions should be addressed to Hella Gebhardt Rønnebæk, Chief Analyst, phone +45 4513 2068.

Attachment

• 20261005_2 Bilag_PDF

HONG KONG, Oct. 05, 2026 (GLOBE NEWSWIRE) — AGM Group Holdings Inc. (NASDAQ: AGMH, “AGM Group” or the “Company”), an integrated technology company specializing in the assembling and sales of high-performance hardware and computing equipment, today announced the closing of its previously announced private placement of Class A ordinary shares, par value US$0.05 per share, at a purchase price of US$0.6305 per share (the “Private Placement”).

Pursuant to the share purchase agreement, dated September 17, 2026 (the “Purchase Agreement”), entered into with an investor (the “Purchaser”), the Company agreed to issue and sell the Shares for aggregate gross proceeds of up to US$11.0 million. The closing of the US$11.0 million Private Placement occurred on October 5, 2026.

The Company intends to use the net proceeds from the Private Placement for general corporate purposes, including working capital, project development, and other strategic initiatives. The financing is expected to strengthen AGM Group’s capital base and support its continued development as a Nasdaq-listed company.

The securities sold in the Private Placement were offered and sold in a transaction exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), and applicable state securities laws. The securities have not been registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About AGM Group Holdings Inc.
AGM Group Holdings Inc. (NASDAQ: AGMH) is an integrated technology company specializing in the assembling and sales of high-performance hardware and computing equipment. With a mission to become a key participant and contributor in the global blockchain ecosystem, AGMH focuses on the research and development of blockchain-oriented Application-Specific Integrated Circuit (“ASIC”) chips, the assembling and sales of high-end crypto miners for Bitcoin and other cryptocurrencies. For more information, please visit: www.agmhgroup.com

Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “assesses,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For more information, please contact:

AGM GROUP HOLDINGS INC.
Investor Relations Department
Email: ir@agmhgroup.com
https://agmhgroup.com/

To Nasdaq Copenhagen A/S

Executive Management Bernstorffsgade 40 DK-1577 København V www.rd.dk Telephone +45 7012 5300 5 October 2026

Company Announcement 05.10.2026

Repayments, Realkredit Danmark A/S

Pursuant to §24 of the Capital Markets Act, Realkredit Danmark A/S hereby publishes repayments as at
1 October 2026.
Please find the data in the attached file.

The information will also be available on www.rd.dk.

Yours sincerely

The Executive Management

Any additional questions should be addressed to Hella Gebhardt Rønnebæk, Chief Analyst, phone +45 4513 2068.

Attachment

• 20261005_2 Bilag

A new patent application covers Polyrizon’s proprietary mucoadhesive platform and its potential applications in nasal drug delivery.

Raanana, Israel, Oct. 05, 2026 (GLOBE NEWSWIRE) —  Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a clinical-stage biotechnology company specializing in the development of innovative intranasal hydrogels, today announced that it has filed a new U.S. divisional patent application with the United States Patent and Trademark Office (USPTO), further expanding the Company’s intellectual property portfolio relating to its proprietary mucoadhesive technology.

The divisional application, titled “Mucoadhesive Polymers for Nasal Drug Delivery,” was assigned U.S. Patent Application No. 19/823,285.

The new application is part of Polyrizon’s broader patent family covering its proprietary mucoadhesive polymer technology. The technology is based on polymeric compositions designed for application to mucosal surfaces and capable of forming a continuous and durable layer upon contact with mucosal tissue.

The underlying technology is designed to support a range of potential applications, including the use of mucoadhesive formulations as a platform for the local or systemic delivery of therapeutic agents through mucosal tissues, including the nasal mucosa. The patent family describes the potential incorporation of therapeutic active ingredients into the mucoadhesive compositions, providing a technological foundation for the development of intranasal drug delivery systems.

The divisional filing enables Polyrizon to pursue additional patent protection for distinct aspects and applications of its technology while maintaining its connection to the Company’s existing U.S. patent family.

Tomer Izraeli, Chief Executive Officer of Polyrizon, commented: “This new U.S. patent filing represents another step in strengthening the intellectual property foundation supporting our intranasal technology platform. We believe our mucoadhesive technology has potential beyond stand-alone barrier applications, particularly as a platform for delivering therapeutic agents through the nasal mucosa. Pursuing additional  patent protection for these applications is an important part of our strategy as we continue to explore the broader potential of our technology.”

Polyrizon continues to develop its proprietary mucoadhesive technology for both stand-alone intranasal products and potential drug delivery applications. The Company believes the ability of its platform to provide prolonged interaction with mucosal surfaces may offer opportunities for the development of new approaches to local and systemic intranasal delivery.

About Polyrizon

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain ^TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target, or T&T. For more information, please visit https://polyrizon-biotech.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential applications of its mucoadhesive technology, including as a platform for the local or systemic delivery of therapeutic agents through mucosal tissues; the potential benefits and opportunities associated with prolonged interaction with mucosal surfaces; the Company’s ability to obtain additional patent protection for its technology; and the Company’s plans to continue developing and exploring applications of its technology. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.

Contacts:

Michal Efraty
Investor Relations
IR@polyrizon-biotech.com